Summary
- Summary pending editorial review.
Key Facts
- Key facts pending editorial review.
Strategic angle: Novo Nordisk and Hims & Hers have reached a deal that, for now, appears to end their bitter dispute around Hims’ sale of compounded versions of Novo’s blockbuster obesity drug.